Order Article Reprints

Bauman JE, Ohr J, Gooding WE, Ferris RL, Duvvuri U, Kim S, Johnson JT, Soloff AC, Wallweber G, Winslow J, et al. Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer. Cancers. 2020; 12(6):1537. https://doi.org/10.3390/cancers12061537

Bauman, Julie E., James Ohr, William E. Gooding, Robert L. Ferris, Umamaheswar Duvvuri, Seungwon Kim, Jonas T. Johnson, Adam C. Soloff, Gerald Wallweber, John Winslow, and et al. 2020. "Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer" Cancers 12, no. 6: 1537. https://doi.org/10.3390/cancers12061537

Bauman, J. E., Ohr, J., Gooding, W. E., Ferris, R. L., Duvvuri, U., Kim, S., Johnson, J. T., Soloff, A. C., Wallweber, G., Winslow, J., Gaither-Davis, A., Grandis, J. R., & Stabile, L. P. (2020). Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer. Cancers, 12(6), 1537. https://doi.org/10.3390/cancers12061537